Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2009

01-01-2009 | Erratum

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Login to get access

Excerpt

Unfortunately a mistake was introduced in Table 4. Please find below the correct table.
Table 4
Maximum toxicity of diarrhea events
 
CTC grade (%)
Patients (N)
Lapatinib
No lapatinib
L
No L
All
G1/2
G3
G4
All
G1/2
G3
G4
Pooled analysis
All studies
1,417
676
54
45
9
<1
24
20
4
0
Breast
936
477
58
46
11.1
<1
31
26
5
0
Other solid tumors
481
199
48
44
4
<1
6
5
1
0
Lapatinib monotherapy
926
N/A
51
45
6
<1
N/A
N/A
N/A
N/A
Lapatinib + capecitabinea
198
191
65
51
13
1
40
30
10
0
Taxane analysis
Lapatinib + taxanesb
401
286
48
39
9
<1
26
24
1
0
No lapatinib is monotherapy with either hormones (n = 197), capecitabine (n = 191), or paclitaxel (n = 286)
CTC, Common toxicity criteria
aEGF100151
bEGF10009, EGF10021, and EGF30001
Metadata
Title
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
Publication date
01-01-2009
Published in
Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9971-y

Other articles of this Issue 2/2009

Breast Cancer Research and Treatment 2/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine